Evidence map›Paper›PMID 33396280›Full record

ArticleBiomolecules2020

ADAMTS1 Supports Endothelial Plasticity of Glioblastoma Cells with Relevance for Glioma Progression.

Orlando Serrano-Garrido, Carlos Peris-Torres, Silvia Redondo-García, Helena G Asenjo, María Del Carmen Plaza-Calonge, José Luis Fernandez-Luna, Juan Carlos Rodríguez-Manzaneque

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. The Effect ofMicroorganisms · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Pharmacogenomics and personalized medicine · 2022
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Orlando Serrano-GarridoGENYO, Centre for Genomics and Oncological Research: Pfizer/Universidad de Granada/Junta de Andalucía, Avenida de la Ilustración, 114, 18016 Granada, Spain.
Carlos Peris-TorresGENYO, Centre for Genomics and Oncological Research: Pfizer/Universidad de Granada/Junta de Andalucía, Avenida de la Ilustración, 114, 18016 Granada, Spain.ORCID 0000-0002-9543-034X
Silvia Redondo-GarcíaGENYO, Centre for Genomics and Oncological Research: Pfizer/Universidad de Granada/Junta de Andalucía, Avenida de la Ilustración, 114, 18016 Granada, Spain.ORCID 0000-0002-7883-3817
Helena G AsenjoGENYO, Centre for Genomics and Oncological Research: Pfizer/Universidad de Granada/Junta de Andalucía, Avenida de la Ilustración, 114, 18016 Granada, Spain.ORCID 0000-0003-1904-1606
María Del Carmen Plaza-CalongeGENYO, Centre for Genomics and Oncological Research: Pfizer/Universidad de Granada/Junta de Andalucía, Avenida de la Ilustración, 114, 18016 Granada, Spain.
José Luis Fernandez-LunaMolecular Genetics Unit, Hospital Universitario Marqués de Valdecilla, Avenida Valdecilla, s/n, 39008 Santander, Spain.
Juan Carlos Rodríguez-ManzanequeGENYO, Centre for Genomics and Oncological Research: Pfizer/Universidad de Granada/Junta de Andalucía, Avenida de la Ilustración, 114, 18016 Granada, Spain.ORCID 0000-0001-5951-7029
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESMarqués de Valdecilla University Hospital · ESUniversidad de Panamá · PA

Funding

Consejería de Salud, Junta de Andalucía OH-0028-2018Consejería de Salud, Junta de Andalucía PE-0225-2018Instituto de Salud Carlos III PI16/00345
6 · The paper itself

Abstract

Gliomas in general and the more advanced glioblastomas (GBM) in particular are the most usual tumors of the central nervous system with poor prognosis. GBM patients develop resistance to distinct therapies, in part due to the existence of tumor cell subpopulations with stem-like properties that participate in trans-differentiation events. Within the complex tumor microenvironment, the involvement of extracellular proteases remains poorly understood. The extracellular protease ADAMTS1 has already been reported to contribute to the plasticity of cancer cells. Accordingly, this basic knowledge and the current availability of massive sequencing data from human gliomas, reinforced the development of this work. We first performed an in silico study of ADAMTS1 and endothelial markers in human gliomas, providing the basis to further assess these molecules in several primary glioblastoma-initiating cells and established GBM cells with the ability to acquire an endothelial-like phenotype. Using a co-culture approach of endothelial and GBM cells, we noticed a relevant function of ADAMTS1 in GBM cells leading the organization of endothelial-like networks and, even more significantly, we found a blockade of the formation of tumor-spheres and a deficient response to hypoxia in the absence of ADAMTS1. Our data support a chief role of this protease modulating the phenotypic plasticity of GBM.

Indexed as

ADAMTS1 ProteinCell Line, TumorCell PlasticityDisease ProgressionEndothelial CellsFemaleGene Expression Regulation, NeoplasticGlioblastomaGliomaHumansMaleNeoplastic Stem CellsTumor MicroenvironmentADAMTS1 ProteinADAMTS1 protein, humanADAMTS proteasesendothelial-like phenotypeextracellular metalloproteaseglioblastomaplasticity

Identifiers

PMID33396280
PMCPMC7823850
OpenAlexW3114557402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.